We are excited to share published preclinical data demonstrating the potential of our mucosal vaccine technology platform in enabling therapeutic vaccination against HPV-related cervical dysplasia in the current issue of Vaccines MDPI. “The preclinical data published in Vaccines demonstrate that our mucosal vaccines stimulate T cells to destroy HPV-expressing cells, reducing the size of HPV-derived tumors and increasing the survival of mice bearing these tumors,” said Sean Tucker, Vaxart’s Founder and Chief Scientific Officer. Read more in today’s press release: https://bit.ly/476Tw9y
That’s great news! Now It may be time for Vaxart to show greater commitment to its investors. Since transitioning to a public company, there has been a noticeable lack of engagement with shareholder interests. Perhaps remaining a private entity would have been a more advantageous approach.
Excellent!! Keep up the good work Vaxart!! Your future looks extremely bright!! Bravo!’ 👏
Fantastic update! Keep going and soon this will bring a lot of value to people!
Inspiring! Keep pushing to get across the finish line.
Finally, some good news!
Fantastic update!
Architect Engineering at AT&T
2moCan’t wait to see your stock @1,166.00 per share as in the year 2005. :)